Bone Cancer - Pipeline Review, H2 2011

Description: Bone Cancer - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, ‘Bone Cancer - Pipeline Review, H2 2011’, provides an overview of the Bone Cancer therapeutic pipeline. This report provides information on the therapeutic development for Bone Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Cancer. ‘Bone Cancer - Pipeline Review, H2 2011’ is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bone Cancer.
- A review of the Bone Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bone Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bone Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bone Cancer pipeline depth and focus of Bone Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Bone Cancer Therapeutic Products under Development, Key Players in Bone Cancer Therapeutics, Bone Cancer Pipeline Overview, Bone Cancer Pipeline, Bone Cancer Pipeline Assessment

Contents:

- List of Tables
- List of Figures
- Introduction
- Global Markets Direct Report Coverage
Bone Cancer Overview

Therapeutics Development
An Overview of Pipeline Products for Bone Cancer
Bone Cancer Therapeutics under Development by Companies
Bone Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Bone Cancer Therapeutics - Products under Development by Companies
Bone Cancer Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Bone Cancer Therapeutics Development
Genzyme Corporation
United Therapeutics Corporation
Amgen Inc.
AstraZeneca PLC
Eli Lilly and Company
Genentech, Inc.
Biotec Pharmacon ASA
Daiichi Sankyo Company, Ltd
Merck & Co., Inc.
Infinity Pharmaceuticals, Inc.
ZIOPHARM Oncology, Inc.
Novartis AG
ImClone Systems Incorporated
Genta Incorporated
Enzon Pharmaceuticals, Inc.
Bayer AG
Geron Corporation
Advaxis, Inc.
Hana Biosciences, Inc.
Ariad Pharmaceuticals, Inc.
Medivir AB
Molecular Insight Pharmaceuticals, Inc.
OncoVics Biotech Inc.
Osteologix, Inc.
National Cancer Institute (NCI)
Green Cross Corporation
Galapagos NV
Sareum Holdings plc
Algeta ASA
Simcere Pharmaceutical Group
Merrion Pharmaceuticals Plc
MabVax Therapeutics, Inc.
Digna Biotech, S.L.
Amura Holdings Ltd.
Hawthorn Pharmaceuticals, Inc.
Neotropix, Inc.
Jennerex Biotherapeutics, Inc.
Novimmune SA
Morphogenesis, Inc.
APEIRON Biologics AG
PharmaMar, S.A.
Archer Biosciences, Inc
Targa Therapeutics Corp.
Epeius Biotechnologies Corporation
Bone Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Late Stage Drug Profiles
Xgeva - Drug Profile
Ridaforolimus - Drug Profile
Alpharadin - Drug Profile
Orazol - Drug Profile
Rexin-G - Drug Profile
Carboplatin + Etoposide + Melphalan + Transplantation - Drug Profile
Androgen Blockade Therapy + Zoledronic Acid - Drug Profile
Bevacizumab + Cisplatin + Doxorubicin + Methotrexate + Ifosfamide + Etoposide - Drug Profile
Zoledronate - Drug Profile
Ibandronate - Drug Profile
Zoledronic Acid - Drug Profile
Zometa - Drug Profile
Filgrastim + Cisplatin + Doxorubicin - Drug Profile
Filgrastim + Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Vincristine sulfate + Radiation therapy - Drug Profile
Chemotherapy + Hormone Therapy + Zoledronate - Drug Profile
Trinity Multipotent Stem Cells - Drug Profile
Filgrastim + Carboplatin + Cisplatin + Cyclophosphamide + Dacarbazine + Doxorubicin Hydrochloride + Etoposide Phosphate + Ifosfamide + Isotretinoin + Melphalan + Topotecan Hydrochloride + Vincristine Sulfate + Vindesine - Drug Profile
Zoledronic Acid + Adrimycin + Cisplatinum + Ifosfamide - Drug Profile
Vincristine + Doxorubicin + Ifosfamide + Cyclophosphamide + Etoposide + Busulfan + Melfalan + Peripheral Stem Cells Transplantation - Drug Profile
Methotrexate + Adrimycin + Cisplatin + Ifosfamide - Drug Profile
Methotrexate + Adrimycin + Cisplatin - Drug Profile
Docetaxel - Drug Profile
Dactinomycin + Doxorubicin Hydrochloride + Etoposide + Ifosfamide + Vincristine Sulfate + Radiation Therapy - Drug Profile
Dactinomycin + Busulfan + Doxorubicin Hydrochloride + Etoposide + Ifosfamide + Melphalan + Vincristine Sulfate + Radiation Therapy + Autologous Peripheral Blood Stem Cell Transplantation - Drug Profile
Platinum Based Chemotherapy + Zoledronic Acid - Drug Profile
High Dose Methotrexate - Drug Profile
Filgrastim + Busulfan + Carboplatin + Cyclophosphamide + Doxorubicin hydrochloride + Etoposide phosphate + Melphalan + Vincristine sulfate + Radiation therapy - Drug Profile
Carboplatin + Etoposide + Melphalan + CD133+ Selected Autologous Stem Cell Transplantation - Drug Profile
vincristine + cisplatin + etoposide + cyclophosphamide + caboplatin - Drug Profile
Busulfan - Drug Profile
Adriamycin + Cisplatinum + Ifosfamide - Drug Profile
Filgrastim + Monoclonal Antibody Ch14.18 + Busulfan + Carboplatin + Cyclophosphamide + Etoposide + Isotretinoin + Melphalan + Vincristine Sulfate - Drug Profile
Treosulfan - Drug Profile
Zoledronic acid - Drug Profile
Dexrazoxane + Doxorubicin + Cisplatin + Methotrexate + Ifosfamide + Etoposide - Drug Profile
Dexrazoxane + Doxorubicin + Cisplatin + Methotrexate + Ifosfamide - Drug Profile
CH14.18 - Drug Profile
Vincristine + Topotecan + Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide - Drug Profile
Cyclophosphamide + Prednisone + Gammaglobulin Therapy - Drug Profile
APN311 - Drug Profile
Bone Cancer Therapeutics – Drug Profile Updates
Bone Cancer Therapeutics - Discontinued Products
Bone Cancer - Featured News
Nov 12, 2011: Exelixis's Cabozantinib Phase II Data Demonstrates Reduction In Bone Pain And Narcotic Analgesic Use In Patients With Previously Treated mCRPC
Oct 17, 2011: Infinity Provides Update On Phase II Trial Of IPI-926 In Chondrosarcoma
Sep 29, 2011: Children's Oncology Group And APEIRON To Conduct Phase II Study In Neuroblastoma With APN301
Sep 24, 2011: Bayer Reports Positive Phase III Data Of Alpharadin In Castration-Resistant Prostate Cancer And Symptomatic Bone Metastases
Sep 13, 2011: Bayer To Present New Data On Alpharadin's Pivotal Phase III Study At 2011 ECCO-ESMO Congress
Aug 23, 2011: FDA Grants Fast Track Designation To Bayer's Alpharadin For Castration Resistant Prostate
Cancer In Patients With Bone Metastases
Aug 22, 2011: Amgen Announces PDUFA Date For XGEVA Supplemental Biologics License Application
Jul 15, 2011: Amgen Receives Marketing Authorization For XGEVA In EU
Jun 24, 2011: PCI Biotech Announces Main Results Of Full Phase I/II Study Of Amphinex
Jun 22, 2011: Celsion's ThermoDox Featured In Special Issue Of The Open Nanomedicine Journal
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Bone Cancer, H2 2011
Products under Development for Bone Cancer – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Genzyme Corporation, H2 2011
United Therapeutics Corporation, H2 2011
Amgen Inc., H2 2011
AstraZeneca PLC, H2 2011
Eli Lilly and Company, H2 2011
Genentech, Inc., H2 2011
Biotec Pharmacon ASA, H2 2011
Daichi Sankyo Company, Ltd, H2 2011
Merck & Co., Inc., H2 2011
Infinity Pharmaceuticals, Inc., H2 2011
ZIOPHARM Oncology, Inc., H2 2011
Novartis AG, H2 2011
ImClone Systems Incorporated, H2 2011
Genta Incorporated, H2 2011
Enzon Pharmaceuticals, Inc., H2 2011
Bayer AG, H2 2011
Geron Corporation, H2 2011
Advaxis, Inc., H2 2011
Hana Biosciences, Inc., H2 2011
Ariad Pharmaceuticals, Inc., H2 2011
Medivir AB, H2 2011
Molecular Insight Pharmaceuticals, Inc., H2 2011
Oncolytics Biotech Inc., H2 2011
Osteologix, Inc., H2 2011
National Cancer Institute (NCI), H2 2011
Green Cross Corporation, H2 2011
Galapagos NV, H2 2011
Sareum Holdings plc, H2 2011
Algeta ASA, H2 2011
Simcere Pharmaceutical Group, H2 2011
Merrion Pharmaceuticals Plc, H2 2011
MabVax Therapeutics, Inc., H2 2011
Digna Biotech, S.L., H2 2011
Amura Holdings Ltd., H2 2011
Hawthorn Pharmaceuticals, Inc., H2 2011
Neotropix, Inc., H2 2011
Jennerex Biotherapeutics, Inc., H2 2011
Novimmune SA, H2 2011
List of Figures
Number of Products under Development for Bone Cancer, H2 2011
Products under Development for Bone Cancer – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011

Ordering:
Order Online - http://www.researchandmarkets.com/reports/1964176/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Bone Cancer - Pipeline Review, H2 2011
Web Address: http://www.researchandmarkets.com/reports/1964176/
Office Code: SCD22DX9

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td></td>
<td>USD 500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td></td>
<td>USD 1000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td></td>
<td>USD 1500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof
First Name: ____________________________________________ Last Name: ____________________________________________
Email Address: * ____________________________________________
Job Title: ____________________________________________
Organisation: ____________________________________________
Address: ____________________________________________
City: ____________________________________________
Postal / Zip Code: ____________________________________________
Country: ____________________________________________
Phone Number: ____________________________________________
Fax Number: ____________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World